of facilitating the comprehension of foreign participants in the SEC’s rules and regulations and shall not in any event be construed or interpreted as having effect in substitution for or supplementary
------------------------------------------------------------------ This English version is prepared by Legal Department with the sole purpose of facilitating the comprehension of foreign participants in the SEC’s rules and regulations and shall not in any event be
RC 33/18 16 May 2018 Subject: Notification of the Disposition of Investment Units of Jasmine Broadband Internet Infrastructure Fund To: President of the Stock Exchange of Thailand Jasmine Internat
RC 35/18 17 May 2018 Subject : Notificat ion of the Disposit ion of Investment Units of Jasmine Broadband Internet Infrastructure Fund To: President of the Stock Exchange of Thailand Jasmine Internat
the Internet, and the inconvenience for thorough reading of lengthy registration statements and prospectuses.The proposal is not expected to add much compliance cost because in practice issuers tend to
35% recorded at the end of the year 2018. 2. Profit obtained from the disposal of assets to Jasmine Broadband Internet Infrastructure Fund (“JASIF”) In November 2019, TTTBB entered into the Additional
objective of operating a telecommunications business. By having the first type of internet service license (Providing internet services without its own network) from the National Broadcasting and
sale radio and communications system and internet of thing (IoT) amounting to Baht 91.09 million, revenue from services on radio and communication system and Internet of Thing (IoT) amounting to Baht
management amounting to Baht 41.11 million, revenue from the sale of electricity amounting to Baht 16.97 million, revenue from the sale radio and communications system and internet of thing (IoT) amounting to
, impairment needs to be considered. • Manufacturing: strong currency impacting ability to export • IT / software: including systems, internet, and home entertainment software • Pharma and biotech: merger